172 related articles for article (PubMed ID: 19267863)
1. Determinants of transhepatic cholesterol flux and their relevance for gallstone formation.
Zanlungo S; Rigotti A
Liver Int; 2009 Mar; 29(3):323-30. PubMed ID: 19267863
[TBL] [Abstract][Full Text] [Related]
2. Differences between hepatic and biliary lipid metabolism and secretion in genetically gallstone-susceptible and gallstone-resistant mice.
Xu G; Zhao L; Fuchs M
Chin Med J (Engl); 2002 Sep; 115(9):1292-5. PubMed ID: 12411097
[TBL] [Abstract][Full Text] [Related]
3. Hepatic cholesterol transport from plasma into bile: implications for gallstone disease.
Zanlungo S; Rigotti A; Nervi F
Curr Opin Lipidol; 2004 Jun; 15(3):279-86. PubMed ID: 15166783
[TBL] [Abstract][Full Text] [Related]
4. Metabolic basis of cholesterol gallstone disease.
Cooper AD
Gastroenterol Clin North Am; 1991 Mar; 20(1):21-46. PubMed ID: 2022424
[TBL] [Abstract][Full Text] [Related]
5. From lipid secretion to cholesterol crystallization in bile. Relevance in cholesterol gallstone disease.
Portincasa P; Moschetta A; Palasciano G
Ann Hepatol; 2002; 1(3):121-8. PubMed ID: 15280810
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of cholesterol and pigment gallstones: an update.
Van Erpecum KJ
Clin Res Hepatol Gastroenterol; 2011 Apr; 35(4):281-7. PubMed ID: 21353662
[TBL] [Abstract][Full Text] [Related]
7. Ezetimibe prevents cholesterol gallstone formation in mice.
Zúñiga S; Molina H; Azocar L; Amigo L; Nervi F; Pimentel F; Jarufe N; Arrese M; Lammert F; Miquel JF
Liver Int; 2008 Aug; 28(7):935-47. PubMed ID: 18783541
[TBL] [Abstract][Full Text] [Related]
8. Gallstone disease.
Marschall HU; Einarsson C
J Intern Med; 2007 Jun; 261(6):529-42. PubMed ID: 17547709
[TBL] [Abstract][Full Text] [Related]
9. [Effect of hypolipidemic treatment on the composition of bile and the risk or cholesterol gallstone disease].
Zák A; Zeman M; Hrubant K; Vecka M; Tvrzická E
Cas Lek Cesk; 2007; 146(1):24-34. PubMed ID: 17310581
[TBL] [Abstract][Full Text] [Related]
10. NPC2 is expressed in human and murine liver and secreted into bile: potential implications for body cholesterol homeostasis.
Klein A; Amigo L; Retamal MJ; Morales MG; Miquel JF; Rigotti A; Zanlungo S
Hepatology; 2006 Jan; 43(1):126-33. PubMed ID: 16374838
[TBL] [Abstract][Full Text] [Related]
11. Pathobiology of cholesterol gallstone disease: from equilibrium ternary phase diagram to agents preventing cholesterol crystallization and stone formation.
Portincasa P; Moschetta A; Calamita G; Margari A; Palasciano G
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Mar; 3(1):67-81. PubMed ID: 12570727
[TBL] [Abstract][Full Text] [Related]
12. The molecular and metabolic basis of biliary cholesterol secretion and gallstone disease.
Zanlungo S; Nervi F
Front Biosci; 2003 Sep; 8():s1166-74. PubMed ID: 12957839
[TBL] [Abstract][Full Text] [Related]
13. Effect of Larrea tridentata (creosote bush) on cholesterol gallstones and bile secretion in hamsters.
Arteaga S; Carmona A; Luis J; Andrade-Cetto A; Cárdenas R
J Pharm Pharmacol; 2005 Sep; 57(9):1093-9. PubMed ID: 16105230
[TBL] [Abstract][Full Text] [Related]
14. Effects of leptin on biliary lipids: potential consequences for gallstone formation and therapy in obesity.
Méndez-Sánchez N; Ponciano-Rodrigoez G; Chavez-Tapia N; Uribe M
Curr Drug Targets Immune Endocr Metabol Disord; 2005 Jun; 5(2):203-8. PubMed ID: 16089354
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol gallstone disease.
Portincasa P; Moschetta A; Palasciano G
Lancet; 2006 Jul; 368(9531):230-9. PubMed ID: 16844493
[TBL] [Abstract][Full Text] [Related]
16. Role of diet in cholesterol gallstone formation.
Méndez-Sánchez N; Zamora-Valdés D; Chávez-Tapia NC; Uribe M
Clin Chim Acta; 2007 Feb; 376(1-2):1-8. PubMed ID: 17055469
[TBL] [Abstract][Full Text] [Related]
17. Gallstone disease: Primary and secondary prevention.
Venneman NG; van Erpecum KJ
Best Pract Res Clin Gastroenterol; 2006; 20(6):1063-73. PubMed ID: 17127188
[TBL] [Abstract][Full Text] [Related]
18. Lithogenesis and bile metabolism.
Lambou-Gianoukos S; Heller SJ
Surg Clin North Am; 2008 Dec; 88(6):1175-94, vii. PubMed ID: 18992590
[TBL] [Abstract][Full Text] [Related]
19. Intestinal and hepatic Niemann-Pick C1L1 proteins: future therapeutic targets for cholesterol gallstones disease?
Castro-Torres IG; De la O-Arciniega M; Bravo-Duarte GA; Gallegos-Estudillo J; Domínguez-Ortíz MÁ; Martínez-Vázquez M
Eur J Pharmacol; 2014 Apr; 728():77-81. PubMed ID: 24525336
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol-gallstone formation: more than a biliary lipid defect?
van Erpecum KJ
J Lab Clin Med; 2004 Sep; 144(3):121-3. PubMed ID: 15478277
[No Abstract] [Full Text] [Related]
[Next] [New Search]
